Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927990 · ClinicalTrials.gov registry record
Contrast Volume Reduction During PCI With the Use of a New Assisting Software Package
A clinical trial, sponsored by Philips Clinical & Medical Affairs Global.
- Terminated
- Registry status
- 80
- Enrollment target
NCT02927990: Clinical Trial study, sponsored by Philips Clinical & Medical Affairs Global.
NCT02927990 is a clinical trial that was terminated before completion, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02927990 was terminated before completion, sponsored by Philips Clinical & Medical Affairs Global.
- TERMINATED
- Registry status
- 80 participants
- Enrollment target
Study Summary
The new software package is intended to assist the physician in imaging the coronaries during percutaneous coronary interventions. This study investigates the amount of contrast used during percutaneous coronary interventions with the aid of the new software package. The results of the study will be compared with control group data (before the new software package was installed or after it was removed) to define a possible contrast reduction.
Primary Outcome
Phase 2 not initiated Only phase 1 data was collected
Interventions
- OTHER Percutaneous Coronary Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2019-06-30 |
Why NCT02927990 stopped before completion
NCT02927990 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Percutaneous Coronary Intervention is the first listed.
NCT02927990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02927990 about?
NCT02927990 is a clinical study titled "Contrast Volume Reduction During PCI With the Use of a New Assisting Software Package". The new software package is intended to assist the physician in imaging the coronaries during percutaneous coronary interventions. This study investigates the amount of contrast used during percutaneous coronary interventions with the aid of the new software package. The results of the study will ...
What is the current status of trial NCT02927990?
This trial is currently terminated. The enrollment target is 80 participants. The study started on 2017-12-15. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT02927990?
The interventions under investigation include: Percutaneous Coronary Intervention (OTHER).
Who is sponsoring clinical trial NCT02927990?
This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI